Christopher Palma

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19”.

Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19

medRxiv(2022)10.1101/2022.09.22.22280245

N/A

0.464DataRank · unranked

9 citations

Eyal Kedar, Kevin J. Anstrom, Matthew W. McCarthy, Emily R. Ko, Patricia Segura Nunez +38 more

SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality—a secondary analysis of the ACTIV-1 trial

Therapeutic Advances in Infectious Disease(2025)10.1177/20499361251333617

N/A

0DataRank · unranked

0 citations

Kimi Enders, Huimin Wu, Luis Parra-Rodriguez, Christopher Palma, Katy Saliba +6 more